Immunomodulatory Effects of Different Cellular Therapies of Bone Marrow Origin on Chimerism Induction and Maintenance Across MHC Barriers in a Face Allotransplantation Model

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Archivum Immunologiae et Therapiae Experimentalis

• Publication date

  2016-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00005-015-0380-8PMID 26708158
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐Term Results in Recipients of Combined HLA‐Mismatched Kidney and Bone Marrow Transplantation Without Maintenance Immunosuppression

  2014cited by this paper
• Simultaneous Bone Marrow and Composite Tissue Transplantation in Rats Treated With Nonmyeloablative Conditioning Promotes Tolerance

  2013cited by this paper
• The transfer of host MHC class I protein protects donor cells from NK cell and macrophage‐mediated rejection during hematopoietic stem cell transplantation and engraftment in mice

  2013cited by this paper
• Upper-Extremity Transplantation Using a Cell-Based Protocol to Minimize Immunosuppression

  2013cited by this paper
• Phenotypic and functional characterization of a CD4+ CD25high FOXP3high regulatory T‐cell population in the dog

  2011cited by this paper
• Favoring the risk-benefit balance for upper extremity transplantation--the Pittsburgh Protocol.

  2011cited by this paper
• Feasibility, Reproducibility, Risks and Benefits of Face Transplantation: A Prospective Study of Outcomes

  2011cited by this paper
• Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease

  2011cited by this paper
• Cell fusion of bone marrow cells and somatic cell reprogramming by embryonic stem cells

  2010cited by this paper
• A Concise Guide to Clinical Trials

  2010cited by this paper
• Long-Term Survival of Composite Hemiface/Mandible/Tongue Allografts Correlates With Multilineage Chimerism Development in the Lymphoid and Myeloid Compartments of Recipients

  2010cited by this paper
• Human CD4low CD25high regulatory T cells indiscriminately kill autologous activated T cells

  2009cited by this paper
• Near-total human face transplantation for a severely disfigured patient in the USA.

  2009cited by this paper
• Setting Up, Conducting and Reporting Trials

  2009cited by this paper
• Mesenchymal Stem Cells Prolong Composite Tissue Allotransplant Survival in a Swine Model

  2009cited by this paper
• Bone Marrow Transplantation Results in Human Donor Blood Cells Acquiring and Displaying Mouse Recipient Class I MHC and CD45 Antigens on Their Surface

  2009cited by this paper
• Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model

  2008cited by this paper
• Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate.

  2008cited by this paper
• Effects of Immunosuppressive Drugs On Purified Human B Cells: Evidence Supporting the Use of MMF and Rapamycin

  2008cited by this paper
• Rapid Deletional Peripheral CD8 T Cell Tolerance Induced by Allogeneic Bone Marrow: Role of Donor Class II MHC and B Cells1

  2008cited by this paper
• Allogeneic donor bone marrow cells recovery and infusion after allogeneic face transplantation from the same donor

  2008cited by this paper
• FOXP3 Expression in Human Kidney Transplant Biopsies Is Associated with Rejection and Time Post Transplant but Not with Favorable Outcomes

  2008cited by this paper
• Hematopoietic Stem Cell Engraftment and Seeding Permits Multi‐Lymphoid Chimerism in Vascularized Bone Marrow Transplants

  2008cited by this paper
• HLA-mismatched renal transplantation without maintenance immunosuppression.

  2008cited by this paper
• Donor–origin cell engraftment after intraosseous or intravenous bone marrow transplantation in a rat model

  2007cited by this paper
• Regulatory T cells and T cell depletion: role of immunosuppressive drugs.

  2007cited by this paper
• Mesenchymal Stem Cells Facilitate the Induction of Mixed Hematopoietic Chimerism and Islet Allograft Tolerance without GVHD in the Rat

  2007cited by this paper
• Outcomes 18 months after the first human partial face transplantation.

  2007cited by this paper
• gammadelta T cells: firefighters or fire boosters in the front lines of inflammatory responses.

  2007cited by this paper
• Pathological and Clinical Correlates of FOXP3+ Cells in Renal Allografts during Acute Rejection

  2007cited by this paper
• Immunomodulation by mesenchymal stem cells and clinical experience

  2007cited by this paper
• Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1

  2007cited by this paper
• In Vivo Formation of Unstable Heterokaryons after Liver Damage and Hematopoietic Stem Cell/Progenitor Transplantation

  2006cited by this paper
• Immunomodulatory Effects of Mesenchymal Stem Cells in a Rat Organ Transplant Model

  2006cited by this paper
• Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

  2006cited by this paper
• A Potential Side Effect of Cyclosporin A: Inhibition of CD4+CD25+ Regulatory T Cells in Mice

  2006cited by this paper
• Human mesenchymal stem cells modulate B-cell functions.

  2006cited by this paper
• Bone marrow-derived cells fuse with normal and transformed intestinal stem cells.

  2006cited by this paper
• The Influence of Immunosuppressive Drugs on T- and B-cell Apoptosis via p53-Mediated Pathway In Vitro and In Vivo

  2006cited by this paper
• Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.

  2005cited by this paper
• Strategies to develop chimerism in vascularized skin allografts across MHC barrier

  2005cited by this paper
• Development and Maintenance of Donor-Specific Chimerism in Semi-Allogenic and Fully Major Histocompatibility Complex Mismatched Facial Allograft Transplants

  2005cited by this paper
• Mesenchymal Stem Cells Inhibit the Expression of CD25 (Interleukin‐2 Receptor) and CD38 on Phytohaemagglutinin‐Activated Lymphocytes

  2004cited by this paper
• Composite tissue transplantation in rats: fusion of donor muscle to the recipient site.

  2004cited by this paper
• Bone marrow–derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation

  2004cited by this paper
• Cell fusion is the principal source of bone-marrow-derived hepatocytes

  2003cited by this paper
• Donor-specific tolerance in fully major histocompatibility major histocompatibility complexmismatched limb allograft transplants under an anti-&agr;&bgr; T-cell receptor monoclonal antibody and cyclosporine A protocol

  2003cited by this paper
• Donor-derived hematopoietic stem cells in organ transplantation: technical aspects and hurdles yet to be cleared

  2003cited by this paper
• Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells

  2003cited by this paper
• Fast Hematopoietic Recovery after Bone Marrow Engraftment Needs Physiological Proximity of Stromal and Stem Cells

  2003cited by this paper
• Functional tolerance following face transplantation in the rat.

  2003cited by this paper
• Induction Of Kidney Allograft Tolerance After Transient Lymphohematopoietic Chimerism In Patients With Multiple Myeloma And End-Stage Renal Disease1

  2002cited by this paper
• Induction of tolerance in composite-tissue allografts

  2002cited by this paper
• Postoperative administration of donor B cells induces rat kidney allograft acceptance: lack of association with TH2 cytokine expression in long-term accepted grafts1

  2002cited by this paper
• Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

  2002cited by this paper
• Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion

  2002cited by this paper
• Comparison of long-term immunosuppression for limb transplantation using cyclosporine, tacrolimus, and mycophenolate mofetil: implications for clinical composite tissue transplantation.

  2001cited by this paper
• Requirement for early donor cell chimerism during prolonged survival of murine skin allografts.

  2000cited by this paper
• INVOLVEMENT OF MULTIPLE SUBPOPULATIONS OF HUMAN BONE MARROW CELLS IN THE REGULATION OF ALLOGENEIC CELLULAR IMMUNE RESPONSES1

  2000cited by this paper
• gammadelta T cells regulate mucosally induced tolerance in a dose-dependent fashion.

  1999cited by this paper
• Importance of T cells to accelerated rejection and acceptance of renal allografts in sensitized rat recipients.

  1998cited by this paper
• Origin, kinetics, and function of chimeric B lymphocytes in liver allografts.

  1998cited by this paper
• Donor-specific tolerance induction in composite tissue allografts.

  1998cited by this paper
• Donor resting B cells induce indefinite prolongation of fully allogeneic cardiac grafts when delivered with anti-immunoglobulin-D monoclonal antibody: evidence for tolerogenicity of donor resting B cells in vivo.

  1998cited by this paper
• Rejection of the Component Tissues of Limb Allografts in Rats Immunosuppressed with FK‐506 and Cyclosporine

  1996cited by this paper
• alpha/beta-T cell receptor-directed therapy in rat cardiac allograft recipients. Treatment prior to alloantigen exposure prevents sensitization and abrogates accelerated rejection.

  1995cited by this paper
• Mixed Allogeneic Chimerism And Renal Allograft Tolerance In Cynomolgus Monkeys

  1995cited by this paper
• T cell-dependent B cell activation.

  1993cited by this paper
• THE REQUIREMENT FOR ALLOGENEIC CHIMERISM FOR SECOND TRANSFER OF TOLERANCE FROM MIXED ALLOGENEIC CHIMERAS (A + B → A) TO SECONDARY RECIPIENTS

  1992cited by this paper
• Cell migration, chimerism, and graft acceptance.

  1992cited by this paper
• Relative Antigenicity of Components of a Vascularized Limb Allograft

  1991cited by this paper
• Molecular and antigenic heterogeneity of the rat leukocyte‐common antigen from thymocytes and T and B lymphocytes

  1985cited by this paper
• T Cell‐Dependent B Cell Activation

  1984cited by this paper
• Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt.

  1976cited by this paper
• ORGAN TRANSPLANTATION (SKIN, KIDNEY, HEART) AND THE PLASTIC SURGEON

  1971cited by this paper
• The fate of skin homografts in man.

  1943cited by this paper

• Long-Term Safety and Efficacy of Systemic DT-DEC01 Cell Therapy in Non-Ambulatory Duchenne Muscular Dystrophy Patients: a 24-Month Clinical Evaluation

  2025cites this paper
• Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy

  2024cites this paper
• Transplantation of Donor–Recipient Chimeric Cells Restores Peripheral Blood Cell Populations and Increases Survival after Total Body Irradiation-Induced Injury in a Rat Experimental Model

  2024cites this paper
• Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration

  2024cites this paper
• Donor-Recipient Chimeric Cell Transplantation as the Bridging Therapy for Mitigating Total Body Irradiation-Induced Injury

  2024cites this paper
• Biodistribution and Safety of Human Multi-Chimeric Cells After Systemic Intraosseous and Intravenous Administration in the Experimental Mouse Model

  2024cites this paper
• Novel Human Umbilical Di-Chimeric (HUDC) cell therapy for transplantation without life-long immunosuppression

  2023cites this paper
• Novel cell-based strategies for immunomodulation in vascularized composite allotransplantation

  2023cites this paper
• Human Multi-Chimeric Cell (HMCC) Therapy as a Novel Approach for Tolerance Induction in Transplantation

  2023influential citation
• Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up

  2023cites this paper
• A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies

  2023cites this paper
• Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy

  2022cites this paper
• Creation of human hematopoietic chimeric cell (HHCC) line as a novel strategy for tolerance induction in transplantation

  2022cites this paper
• Immunosuppressed Miniswine as a Model for Testing Cell Therapy Success: Experience With Implants of Human Salivary Stem/Progenitor Cell Constructs

  2021cites this paper
• Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts

  2021influential citation
• Development of Donor Recipient Chimeric Cells of bone marrow origin as a novel approach for tolerance induction in transplantation.

  2021cites this paper
• Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy

  2021cites this paper
• The Positive Impact of Donor Bone Marrow Cells Transplantation into Immunoprivileged Compartments on the Survival of Vascularized Skin Allografts

  2021cites this paper
• A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models.

  2021cites this paper
• Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy

  2021cites this paper
• Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model

  2020cites this paper
• The past the present and the future of face transplantation

  2020cites this paper
• Innovations and Future Directions in Head and Neck Microsurgical Reconstruction.

  2020cites this paper
• The effect of thymus transplantation on donor‐specific chimerism in the rat model of composite osseomusculocutaneous sternum, ribs, thymus, pectoralis muscles, and skin allotransplantation

  2020cites this paper
• Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy

  2019cites this paper
• The differentiation of mesenchymal stem cells to vascular cells regulated by the HMGB1/RAGE axis: its application in cell therapy for transplant arteriosclerosis

  2018cites this paper
• Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy

  2018cites this paper
• Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy

  2018cites this paper
• Innovations and Future Directions in Head and Neck Microsurgical Reconstruction.

  2017cites this paper
• Bone marrow chimerism as a strategy to produce tolerance in solid organ allotransplantation

  2016cites this paper
• Immunomodulatory Role of Mesenchymal Stem Cell Therapy in Vascularized Composite Allotransplantation

  2016cites this paper
• Saving face: The search for alternatives to life-long immunosuppression for face transplants

  2016cites this paper
• The miracle of face transplantation after 10 years.

  2016cites this paper